Press Releases

DiaMedica Therapeutics Announces Results From Annual General and Special Meeting of Shareholders

Download PDF

MINNEAPOLIS, Nov. 06, 2018 (GLOBE NEWSWIRE) -- DiaMedica Therapeutics Inc. (TSX-V:DMA) (OTCQB:DMCAF), a clinical stage biopharmaceutical company, today announced the voting results from its Annual General and Special Shareholders Meeting held on November 6, 2018. A total of 51.4% of the issued and outstanding common shares of the Company were present either in person or by proxy at the meeting.

The following five nominees proposed by the Company were elected as Directors of DiaMedica to serve until the Company’s next Annual General Meeting of Shareholders. The vote results were as follows:

Dr. Michael Giuffre 56,984,552 99.87% 71,750 0.13%
James Parsons 57,055,102 100% 1,200 0%
Rick Pauls 57,038,252 99.97% 18,050 0.03%
Richard Pilnik 57,045,102 99.98% 11,200 0.02%
Zhenyu "Jerry" Xiao 57,055,102 100% 1,200 0%

DiaMedica shareholders also approved all ballot resolutions, with a minimum of 95.5% of votes cast in favor of each resolution, placed before the meeting and as outlined in the Management Information Circular dated September 30, 2018. The Company’s Management Information Circular is available at for more details on the matters covered at the meeting. Final voting results on all matters voted on at the meeting will also be filed on SEDAR.

About DiaMedica Therapeutics Inc.

DiaMedica Therapeutics is a clinical stage biopharmaceutical company focused on developing novel treatments for neurological and kidney diseases. DiaMedica’s common shares are listed on the TSX Venture Exchange under the trading symbol “DMA” and quoted on the OTCQB marketplace under the trading symbol “DMCAF”. For more information, please visit Follow us on social media – Twitter, LinkedIn.

For further information, please contact:

Paul Papi
Vice President of Business Development
DiaMedica Therapeutics Inc.
Two Carlson Parkway, Suite 260
Minneapolis, MN
Phone: (617) 899-5941

Tweet this!



Source: DiaMedica Therapeutics Inc.